- This event has passed.
“After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction.” – The New York Times, May 9, 2021
It is a bright new world for psychedelics, once revered as the key to consciousness for the flower children of the Cultural Revolution, then outlawed as big pharma swooped in to corner and market opioid, antidepressant, mood-stabilizing, and antipsychotic drugs —to great effect and with massive profits. But now, convincing recent studies demonstrate that certain psychedelic substances can help relieve anxiety, depression, PTSD, addiction, and fear of death for the terminally ill. They can also be used in controlled environments to help individuals expand their very sense of being. State and city governments across the country are beginning to loosen restrictions on certain psychedelic drugs, the first step in what some hope will lead to the federal decriminalization of psychedelics for therapeutic and even recreational use. Our panel of distinguished guests will talk about their mission to make sure that these drugs are available to not only those suffering from mental illness, but for those who want to channel their use for personal growth. The panel will be led by our CCAE friend Anne St. Goar, who has witnessed the value of psychedelics in her treatment of PTSD patients.
Anne St. Goar, M.D. | Board Member of Boston Psychedelic Research Group
Mary Cosimano, LMSW | Director of Guide/Facilitator Services, Johns Hopkins Center for Psychedelic and Consciousness Research
Rick Doblin, Ph.D. | Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS)
Rachael Petersen | Psychedelics and Religion Program Director, The Riverstyx Foundation